Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1016151 | 1.00 | CES2 (0.39) | CES2CES1MAPTSMN1; SMN2TSHR | |
| SCHEMBL1014911 | 0.98 | CES2 (0.42) | CES2CES1MAPTSMN1; SMN2TSHR | |
| SCHEMBL1014910 | 0.98 | CES2 (0.42) | CES2CES1MAPTSMN1; SMN2TSHR | |
| SCHEMBL1014889 | 0.97 | MAPT (0.35) | CES2CES1MAPT | |
| SCHEMBL1014891 | 0.97 | MAPT (0.35) | CES2CES1MAPT | |
| SCHEMBL1015828 | 0.93 | MAPT (0.36) | MAPT | |
| SCHEMBL1015830 | 0.93 | MAPT (0.36) | MAPT | |
| SCHEMBL31587724 | 0.93 | MAPT (0.36) | MAPT | |
| SCHEMBL21960394 | 0.85 | RECQL (0.39) | MAPT | |
| SCHEMBL30550006 | 0.82 | CYP2C9 (0.44) | CES2CES1MAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011049520-A1 | ADAMANTYL IMINOCARBONYL-SUBSTITUTED PYRIMIDINES AS INHIBITORS OF 1 1 BETAHSD1 | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011049520-A1 | ADAMANTYL IMINOCARBONYL-SUBSTITUTED PYRIMIDINES AS INHIBITORS OF 1 1 BETAHSD1 | ASTRAZENECA AB (SE) | 2011-04-28 | — | — | WO | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
| EP-2271629-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| WO-2009130496-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-29 | — | — | WO | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264401-A1 | SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281 | CYP2S1, HSD11B1, HSD3B1 | CES2 297/4885CES1 79/4885MAPT 4375/4885 |
| US-20110092526-A1 | Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826 | HSD11B1, HSD17B11, HSD3B1 | CES2 794/4885CES1 74/4885MAPT 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.